Content area
Abstract
Poziotinib in breast cancer Phase 2 trial results presented by Yeon Hee Park (Sungkyunkwan University, Seoul, South Korea), show the pan-HER tyrosine-kinase inhibitor poziotinib is active in HER2-positive metastatic breast cancer. 106 patients whose disease had progressed after at least two HER2-directed regimens were given poziotinib 12 mg once daily. Alectinib in NSCLC Silvia Novello (University of Turin, Turin, Italy) presented the results of the randomised phase 3 ALUR study in previously treated ALK mutation-positive non-small-cell lung cancer. 107 patients were randomly assigned (2:1) to receive alectenib (n=72) or chemotherapy (pemetrexed or docetaxel; n=35). 493 postmenopausal women who had received no previous systemic therapy in the metastatic setting were randomly assigned (2:1) to receive non-steroidal aromatase inhibitors plus either abemaciclib of 150 mg twice daily (n=328) or placebo (n=165).